The University of Southampton
University of Southampton Institutional Repository

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.

Glucose-lowering drugs, Metabolic dysfunction-associated fatty liver disease, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus
2287-2728
725-738
Miao, Lei
965e629f-454b-4d67-b239-78fbf1873275
Xu, Jing
1274e669-2f05-4848-849e-de7ad2636cec
Targher, Giovanni
119a42ae-1245-42c7-8644-9881fadcd76e
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Zheng, Ming-Hua
cc3ddc1b-7fb7-43ab-a4bd-8134c289bca8
Miao, Lei
965e629f-454b-4d67-b239-78fbf1873275
Xu, Jing
1274e669-2f05-4848-849e-de7ad2636cec
Targher, Giovanni
119a42ae-1245-42c7-8644-9881fadcd76e
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Zheng, Ming-Hua
cc3ddc1b-7fb7-43ab-a4bd-8134c289bca8

Miao, Lei, Xu, Jing, Targher, Giovanni, Byrne, Christopher and Zheng, Ming-Hua (2022) Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. Clinical and Molecular Hepatology, 28 (4), 725-738. (doi:10.3350/cmh.2022.0015).

Record type: Review

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.

Text
Manuscript_R1 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (423kB)
Text
Table 1 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (191kB)
Text
Table 2 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (172kB)
Image
Figure 1 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 2 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 3 - Accepted Manuscript
Restricted to Repository staff only
Request a copy

Show all 6 downloads.

More information

Accepted/In Press date: 11 March 2022
e-pub ahead of print date: 14 March 2022
Published date: 14 March 2022
Additional Information: Funding Information: This work was supported by grants from the National Natural Science Foundation of China (No. 82070588), High Level Creative Talents from the Department of Public Health in Zhejiang Province (No. S2032102600032), Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK. This work is a part of the PERSONS study. Funding Information: This work was supported by grants from the National Natural Science Foundation of China (No. 82070588), High Level Creative Talents from the Department of Public Health in Zhejiang Province (No. S2032102600032), Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the University School of Medicine of Ve-rona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK. This work is a part of the PERSONS study. Publisher Copyright: © 2022 by Korean Association for the Study of the Liver.
Keywords: Glucose-lowering drugs, Metabolic dysfunction-associated fatty liver disease, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus

Identifiers

Local EPrints ID: 455954
URI: http://eprints.soton.ac.uk/id/eprint/455954
ISSN: 2287-2728
PURE UUID: 4aa69830-c729-4006-8896-8dce90df5721
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 11 Apr 2022 16:36
Last modified: 17 Mar 2024 02:49

Export record

Altmetrics

Contributors

Author: Lei Miao
Author: Jing Xu
Author: Giovanni Targher
Author: Ming-Hua Zheng

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×